BioSpace News Archive

The American College of Osteopathic Emergency Physicians (ACOEP), working in partnership with Chicago’s Public Safety Departments, presents a Mass Casualty Incident Simulation on October 20th in Chicago, Illinois.

Grand Rounds has been named to the Forbes 2018 Cloud 100, the definitive list of the top 100 private cloud companies in the world, published by Forbes in collaboration with Bessemer Venture Partners and Salesforce Ventures.

Life Spine announced today first clinical cases of the Life Spine’s NAUTILUS Thoracolumbar Spinal Fixation System with Dr. Jose Antonio Canales and Dr. Antonio Hurtado Padilla, surgeons specializing in deformity correction at Shriners Hospital, Mexico City.

The interviews will cover timely topics with some of the country’s leading healthcare compliance experts

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older.

Viracor Eurofins announced the addition of a new cytomegalovirus (CMV) gene sequencing assay for resistance to letermovir, the most recent FDA-approved CMV antiviral for use in adult Hematopoietic Stem Cell Transplant (HSCT) patients

CUBEX LLC, the leading provider of pharmacy and supply management technology to the animal health market, announced the introduction CUBEX® Tower, a solution for veterinarians looking to reduce the legal and financial risks associated with opioids and other controlled substances, while also driving profit through reduction of missed charges.

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. (“Global Blood” or the “Company”) (NASDAQ: GBT).

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against OPKO Health, Inc. (“OPKO” or the “Company) (NASDAQ: OPK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired OPKO securities between September 26, 2013 and September 7, 2018,

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.